Dose Escalation and Expansion of Abbv-383 in Combination with Anti-Cancer Regimens in Relapsed or Refractory Multiple Myeloma

被引:2
|
作者
Rodriguez, Cesar [1 ]
Weisel, Katja [2 ]
Baz, Rachid C. [3 ]
Polepally, Akshanth R. [4 ]
Ross, Jeremy A. [4 ]
Jin, Ziyi [4 ]
D'Amico, Kristin [4 ]
Bueno, Orlando F. [4 ]
Fleming, Leanne Lash [4 ]
Voorhees, Peter M. [5 ]
机构
[1] Wake Forest Univ Sch Med, Med Oncol & Hematol, Winston Salem, NC USA
[2] Univ Med Ctr Hamburg Eppendorf, Dept Oncol Hematol & Bone Marrow Transplantat, Sect Pneumol, Hamburg, Germany
[3] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA
[4] AbbVie Inc, N Chicago, IL USA
[5] Atrium Hlth Wake Forest Baptist, Levine Canc Inst, Dept Hematol Oncol & Blood Disorders, Plasma Cell Disorders Sect, Charlotte, NC USA
关键词
D O I
10.1182/blood-2022-157977
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:7326 / 7327
页数:2
相关论文
共 50 条
  • [1] Exposure-response analyses for optimal therapeutic dose selection of ABBV-383 in patients with relapsed/refractory multiple myeloma (RRMM)
    Polepally, Akshanth
    Badillo, Jesus D.
    de Almeida, Carla Biesdorf
    Voorhees, Peter M.
    D'Souza, Anita
    Kumar, Shaji
    Bueno, Orlando Felix
    Rosenberg, Tanya
    Pothacamury, Rajvineeth Kumar
    Talati, Chetasi
    Menon, Rajeev
    Mensing, Sven
    Engelhardt, Benjamin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] Phase Ib Study Investigating the Safety, Pharmacokinetics, and Efficacy of Subcutaneous Administration of ABBV-383 in Patients With Relapsed/Refractory Multiple Myeloma
    Gatt, Moshe
    Magen, Hila
    McKay, John
    Karlin, Lionel
    Touzeau, Cyrille
    Vincent, Laure
    Kapoor, Prashant
    Leleu, Xavier
    Uchida, Toshiki
    Weisel, Katja
    Bueno, Orlando
    Rosenberg, Tanya
    Ahsan, Aarif
    Jin, Ziyi
    Polepally, Akshanth
    Talati, Chetasi
    Pothacamury, Rajvineeth
    Chhabra, Saurabh
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S54 - S55
  • [3] Efficacy and Safety of ABBV-383, a BCMA Bispecific Antibody, in Black Patients With Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis of a Phase 1 Trial
    D'Souza, Anita
    Rodriguez-Valdes, Cesar
    Kumar, Shaji
    Chung, Alfred
    Tuchman, Sascha
    Safah, Hana
    Weisel, Katja
    Teipel, Raphael
    Korde, Neha
    Vij, Ravi
    Bueno, Orlando
    Rosenberg, Tanya
    Pothacamury, Rajvineeth
    Polepally, Akshanth
    Ahsan, Aarif
    Lee, Shane
    Jin, Ziyi
    Spence, Shelli
    Talati, Chetasi
    McKay, John
    Voorhees, Peter M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S48 - S48
  • [4] Efficacy, safety, and determination of RP2D of ABBV-383, a BCMA bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).
    Valdes, Cesar Rodriguez
    Voorhees, Peter M.
    D'Souza, Anita
    Chung, Alfred
    Tuchman, Sascha
    Safah, Hana
    Mckay, John T.
    Weisel, Katja C.
    Teipel, Raphael
    Korde, Neha
    Vij, Ravi
    Bueno, Orlando Felix
    Rosenberg, Tanya
    Pothacamury, Rajvineeth Kumar
    Polepally, Akshanth
    Ahsan, Aarif
    Li , Xin
    Jin, Ziyi
    Talati, Chetasi
    Kumar, Shaji
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] ABBV-383, a BCMA-CD3 bispecific antibody, in relapsed/refractory multiple myeloma: a multicenter, phase 1b dose optimization study with step-up dosing
    Baljevic, Muhamed
    Magen, Hila
    Searle, Emma
    Jin, Ziyi
    Strange, Elise
    Svensson, Anders
    Kumar, Shaji
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S162 - S163
  • [6] CERVINO: A Phase 3, Multicenter, Randomized, Open-Label Study of ABBV-383 Compared With Standard Available Therapies in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
    Costa, Luciano
    Mateos Manteca, Maria-Victoria
    Voorhees, Peter M.
    Iida, Shinsuke
    Cole, Craig
    Quach, Hang
    Pothacamury, Rajvineeth
    Bueno, Orlando
    Lee, Shane
    Rosenberg, Tanya
    Talati, Chetasi
    Kumar, Shaji
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S47 - S48
  • [7] Low-dose thalidomide regimens in therapy of relapsed or refractory multiple myeloma
    Zemanova, M.
    Scudla, V.
    Adam, Z.
    Gregora, E.
    Pour, L.
    Minarik, J.
    Pavlicek, P.
    Pika, T.
    Bacovsky, J.
    NEOPLASMA, 2008, 55 (04) : 345 - 349
  • [8] Correlative biomarker analyses for optimal therapeutic dose determination of ABBV-383, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).
    Ahsan, Aarif
    Mantis, Christine
    Luo, Xizhi
    Zhang, Catherine C.
    Valdes, Cesar Rodriguez
    Voorhees, Peter M.
    D'Souza, Anita
    Chung, Alfred
    Tuchman, Sascha
    Safah, Hana
    Mckay, John T.
    Weisel, Katja C.
    Teipel, Raphael
    Korde, Neha
    Vij, Ravi
    Kumar, Shaji
    Bueno, Orlando Felix
    Pothacamury, Rajvineeth Kumar
    Talati, Chetasi
    Ross, Jeremy A.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [9] LEMZOPARLIMAB (TJ011133), AN ANTI-CD47 ANTIBODY, WITH/WITHOUT DEXAMETHASONE PLUS ANTI-MYELOMA REGIMENS FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: A PHASE 1B DOSE ESCALATION AND EXPANSION STUDY
    Stadtmauer, Edward
    Karlin, Lionel
    Weisel, Katja
    Gatt, Moshe Etzion
    Kansagra, Ankit
    Monohan, Gregory
    Yee, Andrew
    Rockow-Magnone, Shayna
    Cordero, Jose
    Hoffman, David
    Bueno, Orlando
    Wu, Kevin
    Gasparetto, Cristina
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A476 - A476
  • [10] Intra-patient dose escalation of panobinostat in patients with relapsed/refractory multiple myeloma
    Isoda, Atsushi
    Ishikawa, Tetsuya
    Miyazawa, Yuri
    Mihara, Masahiro
    Matsumoto, Morio
    Sawamura, Morio
    LEUKEMIA & LYMPHOMA, 2018, 59 (05) : 1277 - 1278